Phathom Pharmaceuticals, Inc. (PHAT)
$9.18+$0.24 (+2.66%) Today
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Tax withholding / forfeiture | 1 | 1,555 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
36 Form 4 filings on record, the earliest from Dec 16, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Heidi Fields | Grant or award | Common Stock | 10,500 | $0.00 | - | |
| Heidi Fields | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Frank Karbe | Grant or award | Common Stock | 10,500 | $0.00 | - | |
| Frank Karbe | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Azmi Nabulsi - Officer | Open-market sale | Common Stock | 1,118 | $8.00 | $9K | |
| Molly Henderson - Officer | Open-market sale | Common Stock | 1,291 | $8.00 | $10K | |
| Frank Karbe | Open-market purchase | Common Stock | 12,500 | $7.93 | $99K | |
| Asit Parikh | Open-market purchase | Common Stock | 10,000 | $8.12 | $81K |
This is as far as the anonymous view goes. Create a free account for all 36 PHAT filings on record.
Phathom Pharmaceuticals, Inc. (PHAT) had 1 insider filing in the last 90 days, with the most recent on 2026-07-16. The full record for PHAT runs to 36 Form 4 filings, the earliest from 2024-12-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of PHAT were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of PHAT were filed in the last 90 days. 5 sales are on record for this company.
This page tracks PHAT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PHAT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
